

Beth T Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6386907/publications.pdf>

Version: 2024-02-01

18
papers

496
citations

1039880

9
h-index

996849

15
g-index

18
all docs

18
docs citations

18
times ranked

748
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P2-12-18-P2-12-18.	0.4	1
2	Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity. <i>Modern Pathology</i> , 2022, 35, 1370-1382.	2.9	5
3	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 7696-7702.	0.7	2
4	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. <i>Modern Pathology</i> , 2021, 34, 603-612.	2.9	15
5	Abstract PS14-21: Refining loco-regional therapy for inflammatory breast cancer protocol in progress. , 2021, , .		0
6	Abstract PS14-09: The impact of non-classic LCIS on the natural history of DCIS. , 2021, , .		0
7	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 449-455.	0.6	3
8	MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. <i>Academic Radiology</i> , 2021, , .	1.3	1
9	Lobular neoplasia detected at MRI-guided biopsy: imaging findings and outcomes. <i>Clinical Imaging</i> , 2021, 78, 171-178.	0.8	5
10	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERBB3 alterations. <i>Modern Pathology</i> , 2020, 33, 1287-1297.	2.9	19
11	Clinicopathological and molecular characterisation of "multiple" classifier™ endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	2.1	205
12	Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. <i>Modern Pathology</i> , 2020, 33, 1746-1752.	2.9	94
13	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. <i>Modern Pathology</i> , 2019, 32, 1257-1262.	2.9	27
14	Pan-TRK Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1693-1700.	2.1	49
15	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 55-61.	0.7	36
16	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.4	2
17	An Update of Mucinous Lesions of the Breast. <i>Surgical Pathology Clinics</i> , 2018, 11, 61-90.	0.7	22
18	Contemporary Evaluation of Breast Lymph Nodes in Anatomic Pathology. <i>American Journal of Clinical Pathology</i> , 2018, 150, 4-17.	0.4	10